CELULARITY INC-A (CELU) Stock Fundamental Analysis

NASDAQ:CELU • US1511902041

1.24 USD
-0.01 (-0.8%)
Last: Feb 26, 2026, 08:15 PM
Fundamental Rating

1

Overall CELU gets a fundamental rating of 1 out of 10. We evaluated CELU against 521 industry peers in the Biotechnology industry. CELU may be in some trouble as it scores bad on both profitability and health. CELU is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CELU had negative earnings in the past year.
  • CELU had a negative operating cash flow in the past year.
  • In the past 5 years CELU reported 4 times negative net income.
  • In the past 5 years CELU always reported negative operating cash flow.
CELU Yearly Net Income VS EBIT VS OCF VS FCFCELU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

  • With a Return On Assets value of -70.65%, CELU is not doing good in the industry: 62.96% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -70.65%
ROE N/A
ROIC N/A
ROA(3y)-58.77%
ROA(5y)-40.28%
ROE(3y)-375.51%
ROE(5y)-245.63%
ROIC(3y)N/A
ROIC(5y)N/A
CELU Yearly ROA, ROE, ROICCELU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

  • CELU's Gross Margin of 50.61% is fine compared to the rest of the industry. CELU outperforms 76.01% of its industry peers.
  • In the last couple of years the Gross Margin of CELU has grown nicely.
  • The Profit Margin and Operating Margin are not available for CELU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.74%
GM growth 5YN/A
CELU Yearly Profit, Operating, Gross MarginsCELU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

0

2. Health

2.1 Basic Checks

  • CELU does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CELU has been increased compared to 1 year ago.
  • Compared to 5 years ago, CELU has more shares outstanding
  • CELU has a worse debt/assets ratio than last year.
CELU Yearly Shares OutstandingCELU Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
CELU Yearly Total Debt VS Total AssetsCELU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • CELU has an Altman-Z score of -13.31. This is a bad value and indicates that CELU is not financially healthy and even has some risk of bankruptcy.
  • CELU's Altman-Z score of -13.31 is on the low side compared to the rest of the industry. CELU is outperformed by 77.74% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.31
ROIC/WACCN/A
WACC5.91%
CELU Yearly LT Debt VS Equity VS FCFCELU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • CELU has a Current Ratio of 0.16. This is a bad value and indicates that CELU is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of CELU (0.16) is worse than 93.28% of its industry peers.
  • A Quick Ratio of 0.12 indicates that CELU may have some problems paying its short term obligations.
  • CELU has a Quick ratio of 0.12. This is amonst the worse of the industry: CELU underperforms 93.47% of its industry peers.
Industry RankSector Rank
Current Ratio 0.16
Quick Ratio 0.12
CELU Yearly Current Assets VS Current LiabilitesCELU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

5

3. Growth

3.1 Past

  • CELU shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -119.42%.
  • The Revenue for CELU has decreased by -15.81% in the past year. This is quite bad
  • The Revenue has been growing by 36.47% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-119.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.97%
Revenue 1Y (TTM)-15.81%
Revenue growth 3Y36.47%
Revenue growth 5YN/A
Sales Q2Q%-43.16%

3.2 Future

  • Based on estimates for the next years, CELU will show a very negative growth in Earnings Per Share. The EPS will decrease by -119.65% on average per year.
  • The Revenue is expected to grow by 98.27% on average over the next years. This is a very strong growth
EPS Next Y-752.63%
EPS Next 2Y-119.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year27.37%
Revenue Next 2Y49.72%
Revenue Next 3Y144.15%
Revenue Next 5Y98.27%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CELU Yearly Revenue VS EstimatesCELU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
CELU Yearly EPS VS EstimatesCELU Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 -2 -4 -6 -8 -10

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CELU. In the last year negative earnings were reported.
  • Also next year CELU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CELU Price Earnings VS Forward Price EarningsCELU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CELU Per share dataCELU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

  • CELU's earnings are expected to decrease with -119.65% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-119.65%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

  • No dividends for CELU!.
Industry RankSector Rank
Dividend Yield 0%

CELULARITY INC-A

NASDAQ:CELU (2/26/2026, 8:15:26 PM)

1.24

-0.01 (-0.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-17
Earnings (Next)05-07
Inst Owners13.47%
Inst Owner Change-2.63%
Ins Owners13.67%
Ins Owner Change10.25%
Market Cap35.76M
Revenue(TTM)40.58M
Net Income(TTM)-80.71M
Analysts82.86
Price Target6.12 (393.55%)
Short Float %2.9%
Short Ratio8.73
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.58%
Min EPS beat(2)-33.33%
Max EPS beat(2)42.48%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.88
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.34
EYN/A
EPS(NY)-2.8
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS1.41
BVpS-0.7
TBVpS-1.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -70.65%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50.61%
FCFM N/A
ROA(3y)-58.77%
ROA(5y)-40.28%
ROE(3y)-375.51%
ROE(5y)-245.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.74%
GM growth 5YN/A
F-Score1
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.16
Quick Ratio 0.12
Altman-Z -13.31
F-Score1
WACC5.91%
ROIC/WACCN/A
Cap/Depr(3y)39.96%
Cap/Depr(5y)N/A
Cap/Sales(3y)16.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-119.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.97%
EPS Next Y-752.63%
EPS Next 2Y-119.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-15.81%
Revenue growth 3Y36.47%
Revenue growth 5YN/A
Sales Q2Q%-43.16%
Revenue Next Year27.37%
Revenue Next 2Y49.72%
Revenue Next 3Y144.15%
Revenue Next 5Y98.27%
EBIT growth 1Y-21.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y88.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y89.75%
OCF growth 3YN/A
OCF growth 5YN/A

CELULARITY INC-A / CELU FAQ

What is the ChartMill fundamental rating of CELULARITY INC-A (CELU) stock?

ChartMill assigns a fundamental rating of 1 / 10 to CELU.


What is the valuation status of CELULARITY INC-A (CELU) stock?

ChartMill assigns a valuation rating of 0 / 10 to CELULARITY INC-A (CELU). This can be considered as Overvalued.


How profitable is CELULARITY INC-A (CELU) stock?

CELULARITY INC-A (CELU) has a profitability rating of 1 / 10.


What is the financial health of CELULARITY INC-A (CELU) stock?

The financial health rating of CELULARITY INC-A (CELU) is 0 / 10.


What is the earnings growth outlook for CELULARITY INC-A?

The Earnings per Share (EPS) of CELULARITY INC-A (CELU) is expected to decline by -752.63% in the next year.